SCHEMBL14044709

SCHEMBL14044709

CCNC(=O)Oc1cn2ncnc(Oc3ccc(N=O)cc3F)c2c1C

nearest known ligand 0.50

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MET P08581 20/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4810931 0.87 MET (0.51) MET
SCHEMBL4817737 0.84 MET (0.49) MET
SCHEMBL4818945 0.78 MET (0.74) MET
SCHEMBL4816753 0.77 MET (0.64) MET
SCHEMBL4047358 0.69 MET (0.47) MET
SCHEMBL4819671 0.67 KDR (0.57) MET
SCHEMBL4390517 0.67 MET (0.57) MET
SCHEMBL5408778 0.67 MET (0.43) MET
SCHEMBL4814662 0.66 MET (0.55) MET
SCHEMBL4812536 0.65 MET (1.00) MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439246-B2 Fused heterocyclic kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-10-21 US disclosed
US-7432373-B2 Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors BRISTOL-MEYERS SQUIBB COMPANY (US) 2008-10-07 US disclosed